The Wnt inhibitory factor 1 (WIF1) antibody is a tool used to detect WIF1. a secreted glycoprotein that antagonizes the Wnt signaling pathway by binding to Wnt proteins and preventing their interaction with cell surface receptors. WIF1 plays a critical role in embryonic development, tissue homeostasis, and stem cell regulation by modulating Wnt activity, a pathway implicated in cell proliferation, differentiation, and survival. Dysregulation of WIF1 is linked to various cancers, including lung, breast, and colorectal carcinomas, where its downregulation via promoter hypermethylation or genetic alterations often correlates with tumor progression, metastasis, and poor prognosis. In research, WIF1 antibodies are employed in techniques like Western blotting, immunohistochemistry, and immunofluorescence to study WIF1 expression patterns, localization, and functional roles in both normal and pathological contexts. Clinically, WIF1 is explored as a potential biomarker for cancer diagnosis or as a therapeutic target, given its tumor-suppressive properties. Studies also suggest its involvement in bone development, neurogenesis, and degenerative diseases, highlighting its broad biological relevance. The development and validation of specific, high-affinity WIF1 antibodies remain essential for advancing mechanistic insights and translational applications in oncology and regenerative medicine.